• Release your full potential

    Be free to be active. Converting knowledge in skin biology into treatment satisfaction

ABOUT US

MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immune-mediated and inflammatory conditions initially focusing on manifestations in the skin. Read more about MC2 Therapeutics.

Platform

When topical dosage form is considered most optimal our PAD Technology™ formulation and drug delivery system offer several unique advantages in the development of potent innovative new topical therapies for immune-mediated and inflammatory conditions, including stability, tolerability, delivery of drugs to target tissue and convenience of use in daily routine. Read more about our platform.

Pipeline

MC2 therapeutics is converting research in skin biology into novel treatment paradigms for immune-mediated and inflammatory conditions initially focusing on manifestations in the skin. Our innovative approach is anchored in deep understanding of skin biology – knowledge that can also be leveraged to inform approaches in other types of immune-mediated and inflammatory diseases outside of this area. Read more about our pipeline.

LATEST NEWS

mc2_news-image-icon-07

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial

  • MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and ...

    READ FULL ARTICLE

mc2_news-image-icon-05

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

  • MC2-25 VLS is a first-in-class drug candidate for urea associated skin diseases using a di-peptide ...

    READ FULL ARTICLE

 

mc2_news-image-icon-07

MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor for Hidradenitis Suppurativa Presented at EADV

  • MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa ...

    READ FULL ARTICLE

mc2_news-image-icon-07

MC2 Therapeutics Acquires Option to Phase 2 Oral Drug Candidate for Hidradenitis Suppurativa and Other Indications

  • Option to exclusively license the rights to develop, manufacture and commercialize “RGRN-305” for all human ...

    READ FULL ARTICLE